Healios K.K. (OTCMKTS:HLOSF) Sees Large Decline in Short Interest

Healios K.K. (OTCMKTS:HLOSF) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 365,900 shares, a decline of 6.4% from the March 31st total of 391,100 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ? days.

Healios K.K. Stock Performance

Shares of OTCMKTS:HLOSF remained flat at 0.99 during trading on Wednesday. Healios K.K. has a 52-week low of 0.94 and a 52-week high of 1.31. The stock’s 50 day simple moving average is 0.95 and its two-hundred day simple moving average is 1.25.

Healios K.K. Company Profile

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease.